Modus Therapeutics to attend BIO-Europe 2015

Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, will be attending BIO-Europe 2015 in Munich, Germany.

BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry and takes place 2-4 November 2015. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.